.jpg "GenMark (NASDAQ: GNMK)")
Yesterday, the COO of GenMark (GNMK), Scott Mendel, sold shares of GNMK for $12.71K.
In addition to Scott Mendel, 9 other GNMK executives reported Sell trades in the last month. Following Scott Mendel’s last GNMK Sell transaction on January 25, 2019, the stock climbed by 0.6%.
See today’s analyst top recommended stocks >>
Currently, GenMark has an average volume of 535.4K. The Company has a Price to Book ratio of 9.1501.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $9.00, reflecting a 32.0% upside.
The insider sentiment on GenMark has been negative according to 102 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of proprietary eSensor electrochemical detection technology. It also manufactures, sells, and supports instruments and molecular tests. The company was founded by Jon Faiz Kayyem on February 12, 2010 and is headquartered in Carlsbad, CA.
